276557 research outputs found
Sort by
Optimizing genetic testing in ovarian cancer: The implementation of the Tumor-First workflow
No full textContains fulltext :
317683.pdf (Publisher’s version ) (Open Access)Each year, approximately 1300 women in the Netherlands are diagnosed with ovarian cancer. About 100 of these women have a hereditary predisposition. A hereditary predisposition informs ovarian cancer treatment decisions and offers at-risk family members the opportunity to take cancer prevention or early intervention measures, which can be life-saving. “Tumor-First” is a new, efficient, and patient-friendly workflow for genetic testing in ovarian cancer. In this PhD project, the nationwide implementation of the Tumor-First workflow in the Netherlands was stimulated and investigated. The results show that, currently, 85% of the ovarian cancer patients follow the proposed pathway. Compared to other new approaches in healthcare, this is a result to be proud of. This has been achieved thanks to the multidisciplinary collaborative efforts of a large group of healthcare professionals and the support of patient organizations. On an international scale, the Netherlands is unique in this large-scale implementation.Radboud University, 14 april 2025Promotores : Hoogerbrugge-van der Linden, N., Ligtenberg, M.J.L., Hullu, J.A. de214 p
Oral health in systemic sclerosis: A scoping review
No full textContains fulltext :
311702.pdf (Publisher’s version ) (Open Access)Background: Limited research on oral health in systematic sclerosis poses a significant challenge for people with systematic sclerosis and health care professionals. We conducted a scoping review to map existing research on oral health–related quality of life in systematic sclerosis across domains including (1) oral manifestations or symptoms, (2) functional consequences, (3) psychosocial aspects, (4) associated patient factors and (5) self-care and management considerations. Methods: We searched MEDLINE, EMBASE, SCOPUS and CINAHL databases to 10 March 2023 for studies on oral health in people with systematic sclerosis. Study data were mapped into pre-specified domains of oral health–related quality of life, subtopics and types of research and reported in tabular form. Results: Of 1460 unique studies reviewed, 91 were eligible and included in the scoping review; of these, 69 (76%) were published as full-text versions, 72 (79%) were from Europe or North America, and 63 (69%) included ⩽50 participants. Only 1 study had >200 participants (N = 382). By domains, 85 (93%) studies reported aspects of oral manifestations or symptoms, with the most common subtopics being oral opening and mandibular function, sicca, periodontitis and soft tissue changes and pathology; 36 (40%) studies provided information on associated patient factors, 23 (25%) on self-care and management, 19 (21%) on psychosocial aspects and 6 (7%) on functional consequences. No studies related to interventions included >50 participants. Conclusion: Most studies on oral health in systematic sclerosis report on manifestations or symptoms, and there are relatively few studies on other important domains. Most studies have been conducted with small samples. Updated systematic reviews should evaluate the quality of existing evidence in domains where enough studies have been done. Large, well-conducted primary studies are needed to address knowledge gaps across domains, including studies that test approaches for supporting oral self-care, improving routine professional care and addressing major disability-causing manifestations.14 p
Hazardous drinking in at-risk young adults: Social context, stress resilience, and emotional wellbeing
No full textContains fulltext :
315700.pdf (Publisher’s version ) (Open Access)Radboud University, 18 februari 2025Promotores : Vink, J.M., Cillessen, A.H.N., Luijten, M., Verhagen, M.180 p
Informal care for people with dementia in Europe.
No full textContains fulltext :
315927.pdf (Publisher’s version ) (Open Access)INTRODUCTION: Informal care estimates for use in health-economic models are lacking. We aimed to estimate the association between informal care time and dementia symptoms across Europe. METHODS: A secondary analysis was performed on 13,529 observations in 5,369 persons from 9 European pooled cohort or trial studies in community-dwelling persons with dementia. A mixed regression model was fitted to time spent on instrumental or basic activities of daily living using disease severity and demographic characteristics. RESULTS: Daily informal care time was 0.5 hours higher in moderate compared to mild and 1.3h higher in severe compared to mild cognitive impairment. Likewise, this was 1.2h and 2.7h for functional disability and 0.3h and 0.6h for behavioral symptoms in the same directions. DISCUSSION: Estimates can be used in both single- and multi-domain health-economic models for dementia in European settings.01 januari 202
Plan Your Defense: A Comparative Analysis of Leakage Detection Methods on RISC-V Cores
No full textContains fulltext :
317380.pdf (Publisher’s version ) (Open Access)SAMOS 202
Regulation of the innate immune phenotype in atherosclerosis: navigating the inflammatory landscape
No full textContains fulltext :
313563.pdf (Publisher’s version ) (Open Access)Radboud University, 30 januari 2025Promotores : Riksen, N.P., Joosten, L.A.B. Co-promotor : Bekkering, S.236 p
mHealth Intervention for Dementia Prevention through lifestyle Optimisation (MIND-PRO) in a primary care setting: protocol for a randomised controlled trial in people with low SES and/or migration background.
No full textContains fulltext :
316994.pdf (Publisher’s version ) (Open Access)INTRODUCTION: The Mobile Health (mHealth) Intervention for Dementia Prevention through lifestyle Optimisation (MIND-PRO) study addresses the increasing prevalence of dementia among populations with lower socio-economic status (SES) and/or a migration background. The study aims to evaluate the effectiveness and implementation of an mHealth intervention designed for self-managing lifestyle modifications with remote coaching to reduce dementia risk factors. METHODS AND ANALYSIS: This prospective randomised open-label blinded end point (PROBE) trial follows a type 2 hybrid effectiveness-implementation design with a 12-month intervention period. It aims to recruit 692 participants in Dutch primary care. Entry criteria include age 50-75 years, low SES and/or migration background, one or more dementia risk factors (hypertension, dyslipidaemia, diabetes mellitus, physical inactivity, smoking, depression and overweight) or manifest cardiovascular disease and possession of a smartphone. Participants are randomised to a coach-supported, interactive app facilitating self-management of dementia risk factors or to a control app with static health information. The primary effectiveness outcome is a composite score of systolic blood pressure, non-high-density lipoprotein cholesterol and body mass index. Implementation outcomes include coverage, adoption, acceptability, appropriateness, feasibility, fidelity, costs and sustainability of the intervention. Secondary outcomes include the Cardiovascular Risk Factors, Ageing and Dementia risk score and its individual risk factors, and disability, physical activity, depressive symptoms, cognitive functioning and daily distance moved. ETHICS AND DISSEMINATION: The MIND-PRO trial is funded by the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10510032120004) and approved by the Ethics Committee of Amsterdam UMC (reference: METC 2023.0770). Results are expected in 2026 and will be submitted for publication in a peer-reviewed journal, and presented at scientific conferences. TRIAL REGISTRATION NUMBER: ISRCTN92928122
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer.
No full textContains fulltext :
315974.pdf (Publisher’s version ) (Open Access)AIMS: Sunitinib exhibits considerable interindividual variability in exposure. While the target total plasma concentration of sunitinib and its active metabolite is 50-87.5 ng/mL for the intermittent dosing schedule, ~10-21% of patients experience higher exposures (>87.5 ng/mL), correlated with an increased risk for toxicity. Previous research identified single nucleotide variants (SNVs) in genes from the sunitinib pharmacokinetic pathway to be associated with efficacy and toxicity. However, significant interindividual variability in exposure remains unexplained. Our aim was to identify genetic variants associated with supratherapeutic exposure of sunitinib. METHODS: This was a genome-wide association study. Cases were identified during routine therapeutic drug monitoring and consisted of patients with dose-normalized sunitinib plasma concentrations >87.5 ng/mL (intermittent dosing) or >75 ng/mL (continuous dosing). Controls were sampled from the historical cohort EuroTARGET who tolerated the standard dose of 50 mg in an intermittent schedule. SNVs were tested for an association with sunitinib exposure. A P-value ≤5 × 10(-8) was considered significant and a P-value between 5 × 10(-8) and 5 × 10(-6) was considered suggestive. RESULTS: Sixty-nine cases and 345 controls were included for association analysis. One SNV (rs6923761), located on the gene glucagon-like peptide 1 receptor, was significantly associated with increased sunitinib exposure (P = 7.86 × 10(-19)). Twelve SNVs were suggestive for an association with sunitinib exposure (P ≤ 5 × 10(-6)). CONCLUSIONS: While rs6923761 is associated with high sunitinib exposure, the underlying mechanism is not yet clarified and warrants further investigation. [Corrections made on 23 September 2024, after first online publication: In the preceding sentence, identifier rs6923671 has been changed to rs6923761 in this version.] We could not confirm the earlier found associations between SNVs in candidate genes involved in the pharmacokinetic pathway of sunitinib and its efficacy and toxicity.01 februari 202
Faraday moments of the Southern Twenty-centimeter All-sky Polarization Survey (STAPS)
No full textContains fulltext :
317941.pdf (Publisher’s version ) (Open Access)15 p